Indonesian health coalition demands return of protections against patent evergreening
The Coalition for Patient Rights Advocacy for Access to Medicines is pursuing a judicial review of the 2024 Indonesian Patent Law, calling for the return of crucial protections against patent evergreening.
US–UK pharma deal sacrifices patients for profit
Access to medicines activists warn the new US–UK pharma deal will have catastrophic impacts, including thousands of preventable deaths each year.
America First Global Health Strategy: a framework for co-opting healthcare in Africa?
The US has announced a series of bilateral health agreements with African countries, sparking concern over pathogen access, benefit sharing, and health sovereignty.
Europe’s Palestine solidarity movement strengthens call to boycott Israeli pharmaceutical company Teva
Pressure is mounting on local governments and public pharmacies to replace Teva products with alternatives not complicit in Israel’s occupation and genocide.
India-UK trade deal threatens access to medicines, activists warn
Activists warn the new India-UK free trade agreement endangers access to medicines by undermining existing protections.
Mexico raises the flag for health sovereignty
Mexico launches a national plan to expand domestic drug production and move toward a free, universal, and public healthcare system.
Reclaiming drug discovery: why we need public pharma
Big Pharma thrives on profiting from publicly funded innovation: but Public Pharma can take back control and put health over profit.
Against the normalization of limited access to CAR-T cell therapies
European hospitals and research centers have a chance to make CAR-T cancer therapies more accessible — the question is whether they’ll take it
EU underfunds medicines while allocating billions to arms
The EU is mobilizing up to €850 billion for so-called defense and armament, missing out on building true security through investment into health
Is Big Pharma’s pollution deregulation campaign fueling the next pandemic?
Big Pharma keeps pushing for weaker pollution standards despite proven risks to human and environmental health
Public Pharma: still a missing debate in mainstream academia
Despite drug shortages and soaring prices, mainstream academia continues to ignore Public Pharma as a solution
WHO Executive Board to discuss substandard medical products: what is it all about?
The WHO Executive Board will discuss global health priorities this week, including substandard and falsified medical products, with key implications for public pharmaceutical initiatives
- Brazil approves end to 6×1 work schedule and reduction of the work week to 40 hours
- Israel kills 31 people in Lebanon on the eve of Eid al-Adha
- Israel carries out sixth consecutive Eid massacre in Gaza
- Far-right Janez Janša to return for fourth government term in Slovenia
- With peace deal nearly final, US launches fresh attacks on Iran
